A Single Center, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics of CRV431 Under Fasted and Fed States in Normal Healthy Volunteer Subjects
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Rencofilstat (Primary)
- Indications Coronavirus infections; COVID 2019 infections; Hepatitis B; Hepatitis C; Hepatitis D; HIV-1 infections; Human papillomavirus infections; Liver cancer; Liver disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; SARS-CoV-2 acute respiratory disease
- Focus Pharmacokinetics
- Sponsors Hepion Pharmaceuticals
Most Recent Events
- 28 Oct 2022 New trial record
- 20 Oct 2022 According to a Hepion Pharmaceuticals media release, results from the study have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development.